{
    "paper_id": "e82bda9e78b47fda3ebd29010b1c515239947d52",
    "metadata": {
        "title": "COVID-19, Low-Molecular-Weight Heparin, and Hemodialysis Keywords COVID-19 \u00b7 Low-molecular-weight heparin \u00b7 Hemodialysis Are Hemodialysis Patients at a Lower Risk for COVID-19 Infection?",
        "authors": [
            {
                "first": "Alessandra",
                "middle": [
                    "F"
                ],
                "last": "Perna",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of Campania Luigi Vanvitelli",
                    "location": {
                        "settlement": "Naples",
                        "country": "Italy"
                    }
                },
                "email": ""
            },
            {
                "first": "Giovanna",
                "middle": [],
                "last": "Capolongo",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of Campania Luigi Vanvitelli",
                    "location": {
                        "settlement": "Naples",
                        "country": "Italy"
                    }
                },
                "email": ""
            },
            {
                "first": "Francesco",
                "middle": [],
                "last": "Trepiccione",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of Campania Luigi Vanvitelli",
                    "location": {
                        "settlement": "Naples",
                        "country": "Italy"
                    }
                },
                "email": ""
            },
            {
                "first": "Mariadelina",
                "middle": [],
                "last": "Simeoni",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of Campania Luigi Vanvitelli",
                    "location": {
                        "settlement": "Naples",
                        "country": "Italy"
                    }
                },
                "email": ""
            },
            {
                "first": "Miriam",
                "middle": [],
                "last": "Zacchia",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of Campania Luigi Vanvitelli",
                    "location": {
                        "settlement": "Naples",
                        "country": "Italy"
                    }
                },
                "email": ""
            },
            {
                "first": "Diego",
                "middle": [],
                "last": "Ingrosso",
                "suffix": "",
                "affiliation": {
                    "laboratory": "",
                    "institution": "University of Campania Luigi Vanvitelli",
                    "location": {
                        "settlement": "Naples",
                        "country": "Italy"
                    }
                },
                "email": ""
            }
        ]
    },
    "abstract": [],
    "body_text": [
        {
            "text": "In an Italian experience, among 200 patients 18 were infected and isolated (9%), and in another unit of 170 patients only 4 were infected [5] . In the Piedmont and Aosta regions, among 2,893 patients 98 were infected (3.4%) during the first month of the epidemic [6] . By the way, in none of the mentioned studies was the mode of anticoagulation during hemodialysis mentioned. While they cast doubts on the open-space hospital model now implemented in many hospitals, which is incompatible with the need to counteract epidemics [7] , these reports also create uncertainty regarding the concept that these patients are at a particularly increased risk for COVID-19.",
            "cite_spans": [
                {
                    "start": 138,
                    "end": 141,
                    "text": "[5]",
                    "ref_id": "BIBREF4"
                },
                {
                    "start": 263,
                    "end": 266,
                    "text": "[6]",
                    "ref_id": "BIBREF5"
                },
                {
                    "start": 528,
                    "end": 531,
                    "text": "[7]",
                    "ref_id": "BIBREF6"
                }
            ],
            "ref_spans": [],
            "section": ""
        },
        {
            "text": "Heparin actually consists of a heterogeneous mixture of sulfomucopolysaccharides, containing also a minimum peptide component of 2 amino acids (glycine and serine). Heparin exerts a binding capacity to both the endothelial surface and various plasmaproteins (Fig. 1) . The molecular weight range of unfractionated heparin (UFH) is 5,000-30,000. Low-molecularweight heparin (LMWH) fractions effectively inhibit the activated factor X (Factor X a ), while exerting a less inhibitory effect on thrombin, compared to the unfractionated forms. It has been shown that LMWH preparations retain their efficacy toward thromboembolisms and, compared to UFH, show increased bioavailability and the need for less frequent administration. Heparin biological activity crucially depends on the endogenous antithrombin anticoagulant [8, 9] . The serine protease inhibitor activity of antithrombin is exerted toward thrombin and Factor X a , resulting in the inhibition of both ( Fig. 1 ) [10] . Congenital or acquired antithrombin deficiency is indeed associated with a high risk of thromboembolic complications and an impaired interaction with heparin. Administration of antithrombin is generally indicated for the prophylaxis of thromboembolic accidents in nephrology (e.g., in patients with nephrotic syndrome) [11] . In addition, it has been shown that during sepsis activation of the extrinsic coagulation pathway, together with a relevant decline of both coagulation inhibition and fibrinolytic mechanisms, may result in a procoagulant state, leading to microvascular thrombosis and multiorgan dysfunction [12] . Antithrombin levels decrease in sepsis and, when low, may predict high mortality [13] . In addition, heparin is utilized in this context, also for its immunomodulatory and anti-inflammatory role [14] .",
            "cite_spans": [
                {
                    "start": 817,
                    "end": 820,
                    "text": "[8,",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 821,
                    "end": 823,
                    "text": "9]",
                    "ref_id": "BIBREF8"
                },
                {
                    "start": 972,
                    "end": 976,
                    "text": "[10]",
                    "ref_id": "BIBREF9"
                },
                {
                    "start": 1298,
                    "end": 1302,
                    "text": "[11]",
                    "ref_id": "BIBREF10"
                },
                {
                    "start": 1596,
                    "end": 1600,
                    "text": "[12]",
                    "ref_id": "BIBREF11"
                },
                {
                    "start": 1684,
                    "end": 1688,
                    "text": "[13]",
                    "ref_id": "BIBREF12"
                },
                {
                    "start": 1798,
                    "end": 1802,
                    "text": "[14]",
                    "ref_id": "BIBREF13"
                }
            ],
            "ref_spans": [
                {
                    "start": 258,
                    "end": 266,
                    "text": "(Fig. 1)",
                    "ref_id": "FIGREF1"
                },
                {
                    "start": 963,
                    "end": 969,
                    "text": "Fig. 1",
                    "ref_id": "FIGREF1"
                }
            ],
            "section": "Hemodialysis and Anticoagulation"
        },
        {
            "text": "During hemodialysis it is necessary to perform anticoagulation of the dialysis circuit to avoid blood clotting in the system due to Factor VII, platelet, and leukocyte activation. Anticoagulation is usually performed utilizing heparin, often in Western Europe in the lowmolecular-weight form [15, 16] , which has some advantages over UFH. Relative to UFH, in fact, LMWH could induce less undesired bleeding after completion of the dialysis session and perhaps less triglyceride reduction.",
            "cite_spans": [
                {
                    "start": 292,
                    "end": 296,
                    "text": "[15,",
                    "ref_id": "BIBREF14"
                },
                {
                    "start": 297,
                    "end": 300,
                    "text": "16]",
                    "ref_id": "BIBREF15"
                }
            ],
            "ref_spans": [],
            "section": "Hemodialysis and Anticoagulation"
        },
        {
            "text": "Heparin-induced thrombocytopenia (HIT) is an immune complex-mediated condition defined as a decrease in platelet counts below 150,000 per mm 3 , with a median nadir of about 55,000 per mm 3 , associated with a positive test for heparin-dependent antibodies [17, 18] . The typical onset pattern (60% of the cases) results in a platelet decline 5-10 days after exposure. The rapid onset pattern (30% of cases) occurs right after the exposure. The delayed onset pattern (\u223c10%) occurs 9.2 days after the start of heparin administration therapy, on average, although signs and symptoms may occur up to 3 weeks after the exposure [18] . Careful evaluation and monitoring should be indeed applied toward the risk of HIT [19] . LMWH offers the advantage of a reduced binding to platelet factor 4, thus decreasing the HIT risk [20] . On the other hand, the shorter size of LMWH may hamper the effectiveness of protamine as an antidote [20] . Useful information is provided by reporting a thrombocyte count of less than 50%, which represents an important red flag [19, 20] . Laboratory tests can then be used to confirm the presence of platelet factor 4 (PF4)/heparin antibodies [21] . Attention should be payed when reporting the presence of activating antibodies against PF4-heparin complexes (PF4-H) to the cut-off point for a positive test (e.g., 1 U/mL) [19] . A score has been developed based on 8 clinical features, each scoring between -2 and +3 [22] . Other scoring systems are also available [18] . Mechanism of action of UFH and LMWH with the major ligand-binding interactions involved. One of the key proteins for the activity of heparin is antithrombin, a serine protease inhibitor (SERPINSC1) that inactivates several clotting factors. Mechanistically, heparin binds to antithrombin, thus exposing the antithrombin protease inhibitor binding site and forming equimolecular complexes with its ligands. Antithrombin uses unique and extensive conformational change mechanisms to inhibit its protease ligands [8] . Heparin increases by orders of magnitude the tendency of antithrombin to interact with a number of plasma proteins. The resulting complex, in particular with thrombin (factor IIa) and factors IXa, Xia, and Xa, inhibits the protease activities of these clotting factors. Heparin indeed works as an antithrombin-protease-inhibiting cofactor without being consumed, and, once the antithrombin-protease complex is formed, heparin is released in its intact conformation, thus repeatedly activating new antithrombin molecules. Heparin biological activity crucially depends indeed on the endogenous antithrombin anticoagulant activity. The role of antithrombin is pivotal in coagulation regulation by shifting thrombin from procoagulant to anticoagulant activity. The presence of heparin dramatically increases the complex stability of antithrombin with the above-mentioned coagulation factors [8, 9] . One important difference between UFH and LMWH is that the interaction of antithrombin with UHF almost equally induces inhibition and degradation of both Xa and thrombin, while LMWH preferentially determines degradation of factor Xa. Various other potential benefits of heparin in COVID-19 have been put forward recently [28] . ",
            "cite_spans": [
                {
                    "start": 257,
                    "end": 261,
                    "text": "[17,",
                    "ref_id": "BIBREF16"
                },
                {
                    "start": 262,
                    "end": 265,
                    "text": "18]",
                    "ref_id": "BIBREF17"
                },
                {
                    "start": 624,
                    "end": 628,
                    "text": "[18]",
                    "ref_id": "BIBREF17"
                },
                {
                    "start": 713,
                    "end": 717,
                    "text": "[19]",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 818,
                    "end": 822,
                    "text": "[20]",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 926,
                    "end": 930,
                    "text": "[20]",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 1054,
                    "end": 1058,
                    "text": "[19,",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 1059,
                    "end": 1062,
                    "text": "20]",
                    "ref_id": "BIBREF19"
                },
                {
                    "start": 1169,
                    "end": 1173,
                    "text": "[21]",
                    "ref_id": "BIBREF20"
                },
                {
                    "start": 1349,
                    "end": 1353,
                    "text": "[19]",
                    "ref_id": "BIBREF18"
                },
                {
                    "start": 1444,
                    "end": 1448,
                    "text": "[22]",
                    "ref_id": "BIBREF21"
                },
                {
                    "start": 1492,
                    "end": 1496,
                    "text": "[18]",
                    "ref_id": "BIBREF17"
                },
                {
                    "start": 2009,
                    "end": 2012,
                    "text": "[8]",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 2902,
                    "end": 2905,
                    "text": "[8,",
                    "ref_id": "BIBREF7"
                },
                {
                    "start": 2906,
                    "end": 2908,
                    "text": "9]",
                    "ref_id": "BIBREF8"
                },
                {
                    "start": 3231,
                    "end": 3235,
                    "text": "[28]",
                    "ref_id": "BIBREF27"
                }
            ],
            "ref_spans": [],
            "section": "Evaluating the Risk of Heparin-Induced Thrombocytopenia"
        },
        {
            "text": "LMWH has some antiviral properties in vitro and it is routinely used in COVID-19 patients to prevent or circumvent the activation of the coagulation cascade induced by inflammation [23] . This is a particularly severe and lethal complication, leading to disseminated intravascular coagulation and venous thromboembolism. In a retrospective study, LMWH therapy reduced interleukin-6 release and activity, which is responsible of the \"cytokine storm,\" and treated patients had also a higher percentage of lymphocytes [24] . LMWH therapy is also associated with better outcomes in severe COVID-19 patients with sepsis-induced coagulopathy and markedly elevated D-dimer levels [25] .",
            "cite_spans": [
                {
                    "start": 181,
                    "end": 185,
                    "text": "[23]",
                    "ref_id": "BIBREF22"
                },
                {
                    "start": 515,
                    "end": 519,
                    "text": "[24]",
                    "ref_id": "BIBREF23"
                },
                {
                    "start": 673,
                    "end": 677,
                    "text": "[25]",
                    "ref_id": "BIBREF24"
                }
            ],
            "ref_spans": [],
            "section": "LMWH and COVID-19"
        },
        {
            "text": "It should be pointed out that uremia offers a unique microenvironment in which the coagulation and anticoagulation balance can be dysregulated in many ways. For example, the presence of anti-protein C and anti-protein S antibodies has been detected [26] , which may critically underscore the acute onset of a procoagulant situation in these patients (already characterized by an increased thrombotic risk). These data indeed may prudentially pose the indication of monitoring protein C and free protein S (Fig. 2) . It can be hypothesized that, upon SARS-Cov-2 infection, the presence of antibodies with potential inhibitory activity on protein C and protein S may even increase the functional effect of an activated protein C (APC) resistance condition, whereas already present in the patient. Testing for APC resistance is indeed advised in these patients. [29] . Protein S in turn is a cofactor of APC for the inactivation of activated coagulation factors VIII a and V a . Only free protein S, i.e., the fraction which is not bound to C4b-binding protein (not shown) in circulation, retains its anticoagulant activity. Activated factor V (factor V a ) procoagulant activity is inactivated by APC-catalyzed cleavage at the Arg506 level, yielding factor V i . Beyond its intrinsic procoagulant activity, Factor V a also exerts an anticoagulant activity as a cofactor for APC and protein S, in inactivation of the procoagulant factor VIII a yielding factor VIII i [30] . This function is also compromised in the presence of factor V resistance to cleavage by APC (APC-R; hatched box), mainly due to the Arg506Gln mutation (factor V Leiden ), which indeed represents the most common cause of APC resistance in the population. ",
            "cite_spans": [
                {
                    "start": 249,
                    "end": 253,
                    "text": "[26]",
                    "ref_id": "BIBREF25"
                },
                {
                    "start": 859,
                    "end": 863,
                    "text": "[29]",
                    "ref_id": "BIBREF28"
                },
                {
                    "start": 1464,
                    "end": 1468,
                    "text": "[30]",
                    "ref_id": "BIBREF29"
                }
            ],
            "ref_spans": [
                {
                    "start": 505,
                    "end": 513,
                    "text": "(Fig. 2)",
                    "ref_id": "FIGREF2"
                }
            ],
            "section": "LMWH and COVID-19"
        },
        {
            "text": "It is therefore possible that hemodialysis patients could be protected with respect to COVID-19 virus infection by the LMWH used in every hemodialysis session. We propose monitoring, in these patients, of the Anti-Factor Xa activity assay [27] , as well as antithrombin, and D-dimer levels, and not just aPTT, in order to possibly even increase the LMWH dosage, in this pandemic period ( Table 1) .",
            "cite_spans": [
                {
                    "start": 239,
                    "end": 243,
                    "text": "[27]",
                    "ref_id": "BIBREF26"
                }
            ],
            "ref_spans": [
                {
                    "start": 388,
                    "end": 396,
                    "text": "Table 1)",
                    "ref_id": "TABREF2"
                }
            ],
            "section": "COVID-19, LMWH, and Hemodialysis: Future Perspectives"
        },
        {
            "text": "The availability of these exams could therefore lead to optimization of LMWH in this patient population.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "COVID-19, LMWH, and Hemodialysis: Future Perspectives"
        },
        {
            "text": "A.F.P. and D.I. received funding from Gnosis, SpA, and EUTox.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Disclosure Statement"
        },
        {
            "text": "None.",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Funding Sources"
        },
        {
            "text": "All of the authors contributed equally to the writing of this paper. ",
            "cite_spans": [],
            "ref_spans": [],
            "section": "Author Contributions"
        }
    ],
    "bib_entries": {
        "BIBREF0": {
            "ref_id": "b0",
            "title": "Epidemiology of acute infections among patients with chronic kidney disease",
            "authors": [
                {
                    "first": "L",
                    "middle": [
                        "S"
                    ],
                    "last": "Dalrymple",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "S"
                    ],
                    "last": "Go",
                    "suffix": ""
                }
            ],
            "year": 2008,
            "venue": "Clin J Am Soc Nephrol",
            "volume": "3",
            "issn": "5",
            "pages": "1487--93",
            "other_ids": {}
        },
        "BIBREF1": {
            "ref_id": "b1",
            "title": "Risk factors for infection-related hospitalization in in-center hemodialysis",
            "authors": [
                {
                    "first": "L",
                    "middle": [
                        "S"
                    ],
                    "last": "Dalrymple",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Mu",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "V"
                    ],
                    "last": "Nguyen",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "S"
                    ],
                    "last": "Romano",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "M"
                    ],
                    "last": "Chertow",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Grimes",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Clin J Am Soc Nephrol",
            "volume": "10",
            "issn": "12",
            "pages": "2170--80",
            "other_ids": {}
        },
        "BIBREF2": {
            "ref_id": "b2",
            "title": "COVID-19 in hemodialysis patients: a report of 5 cases",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Liao",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "He",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Hu",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Wei",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Hong",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Am J Kidney Dis",
            "volume": "",
            "issn": "20",
            "pages": "30612--30612",
            "other_ids": {}
        },
        "BIBREF4": {
            "ref_id": "b4",
            "title": "Practical indications for the prevention and management of SARS-CoV-2 in ambulatory dialysis patients: lessons from the first phase of the epidemics in Lombardy",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Rombol\u00e0",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Heidempergher",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Pedrini",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Farina",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Aucella",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Messa",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Nephrol",
            "volume": "33",
            "issn": "2",
            "pages": "193--199",
            "other_ids": {}
        },
        "BIBREF5": {
            "ref_id": "b5",
            "title": "Working group of the Piedmont and Aosta Valley Section of the SIN. First considerations on the SARS-COV-2 epidemic in the dialysis units of Piedmont and Aosta Valley, Northern Italy",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Manganaro",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Baldovino",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Nephrol",
            "volume": "33",
            "issn": "3",
            "pages": "393--395",
            "other_ids": {}
        },
        "BIBREF6": {
            "ref_id": "b6",
            "title": "Hospitals as health factories and the coronavirus epidemic",
            "authors": [
                {
                    "first": "G",
                    "middle": [
                        "B"
                    ],
                    "last": "Piccoli",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Nephrol",
            "volume": "33",
            "issn": "2",
            "pages": "189--91",
            "other_ids": {}
        },
        "BIBREF7": {
            "ref_id": "b7",
            "title": "An overview of the serpin superfamily",
            "authors": [
                {
                    "first": "R",
                    "middle": [
                        "H"
                    ],
                    "last": "Law",
                    "suffix": ""
                },
                {
                    "first": "Q",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Mcgowan",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "M"
                    ],
                    "last": "Buckle",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [
                        "A"
                    ],
                    "last": "Silverman",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Wong",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Genome Biol",
            "volume": "7",
            "issn": "5",
            "pages": "",
            "other_ids": {}
        },
        "BIBREF8": {
            "ref_id": "b8",
            "title": "Thromboembolic disease due to thermolabile conformational changes of antithrombin Rouen-VI (187 Asn\u2192Asp)",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Bruce",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "J"
                    ],
                    "last": "Perry",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "Y"
                    ],
                    "last": "Borg",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "W"
                    ],
                    "last": "Carrell",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "R"
                    ],
                    "last": "Wardell",
                    "suffix": ""
                }
            ],
            "year": 1994,
            "venue": "J Clin Invest",
            "volume": "94",
            "issn": "6",
            "pages": "2265--74",
            "other_ids": {}
        },
        "BIBREF9": {
            "ref_id": "b9",
            "title": "Molecular genetics of human antithrombin deficiency",
            "authors": [
                {
                    "first": "D",
                    "middle": [
                        "J"
                    ],
                    "last": "Perry",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "W"
                    ],
                    "last": "Carrell",
                    "suffix": ""
                }
            ],
            "year": 1996,
            "venue": "Hum Mutat",
            "volume": "7",
            "issn": "1",
            "pages": "7--22",
            "other_ids": {}
        },
        "BIBREF10": {
            "ref_id": "b10",
            "title": "Prophylaxis with AT III for thromboembolism in nephrotic syndrome: why should it be done?",
            "authors": [
                {
                    "first": "M",
                    "middle": [],
                    "last": "Zaffanello",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Brugnara",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Fanos",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Franchini",
                    "suffix": ""
                }
            ],
            "year": 2009,
            "venue": "Int Urol Nephrol",
            "volume": "41",
            "issn": "3",
            "pages": "713--719",
            "other_ids": {}
        },
        "BIBREF11": {
            "ref_id": "b11",
            "title": "Serum Level of Antithrombin III (ATIII) Could Serve as a Prognostic Biomarker in Neonatal Sepsis",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Samra",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Alghwass",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Elgawhary",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Hassan",
                    "suffix": ""
                },
                {
                    "first": "O",
                    "middle": [],
                    "last": "Bekhit",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Mohamed",
                    "suffix": ""
                }
            ],
            "year": 2019,
            "venue": "Fetal Pediatr Pathol",
            "volume": "38",
            "issn": "4",
            "pages": "290--298",
            "other_ids": {}
        },
        "BIBREF12": {
            "ref_id": "b12",
            "title": "Plasma antithrombin III and protein C levels in early recognition of late-onset sepsis in newborns",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Lauterbach",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Pawlik",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Radziszewska",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Wo\u017aniak",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Rytlewski",
                    "suffix": ""
                }
            ],
            "year": 2006,
            "venue": "Eur J Pediatr",
            "volume": "165",
            "issn": "9",
            "pages": "585--594",
            "other_ids": {}
        },
        "BIBREF13": {
            "ref_id": "b13",
            "title": "The role of heparin in sepsis: much more than just an anticoagulant",
            "authors": [
                {
                    "first": "X",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Ma",
                    "suffix": ""
                }
            ],
            "year": 2017,
            "venue": "Br J Haematol",
            "volume": "179",
            "issn": "3",
            "pages": "389--98",
            "other_ids": {}
        },
        "BIBREF14": {
            "ref_id": "b14",
            "title": "Anticoagulation for intermittent hemodialysis",
            "authors": [
                {
                    "first": "R",
                    "middle": [],
                    "last": "Ouseph",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "A"
                    ],
                    "last": "Ward",
                    "suffix": ""
                }
            ],
            "year": 2000,
            "venue": "Semin Dial",
            "volume": "13",
            "issn": "3",
            "pages": "181--188",
            "other_ids": {}
        },
        "BIBREF15": {
            "ref_id": "b15",
            "title": "An evaluation of four modes of low-dose anticoagulation during intermittent haemodialysis",
            "authors": [
                {
                    "first": "M",
                    "middle": [
                        "S"
                    ],
                    "last": "Skagerlind",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [
                        "G"
                    ],
                    "last": "Stegmayr",
                    "suffix": ""
                }
            ],
            "year": 2018,
            "venue": "Eur J Clin Pharmacol",
            "volume": "74",
            "issn": "3",
            "pages": "267--74",
            "other_ids": {}
        },
        "BIBREF16": {
            "ref_id": "b16",
            "title": "Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin",
            "authors": [
                {
                    "first": "T",
                    "middle": [
                        "E"
                    ],
                    "last": "Warkentin",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "N"
                    ],
                    "last": "Levine",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Hirsh",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [],
                    "last": "Horsewood",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "S"
                    ],
                    "last": "Roberts",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "Gent",
                    "suffix": ""
                }
            ],
            "year": 1995,
            "venue": "N Engl J Med",
            "volume": "332",
            "issn": "20",
            "pages": "1330--1335",
            "other_ids": {}
        },
        "BIBREF17": {
            "ref_id": "b17",
            "title": "Heparin-Induced Thrombocytopenia: A Comprehensive Clinical Review",
            "authors": [
                {
                    "first": "B",
                    "middle": [
                        "S"
                    ],
                    "last": "Salter",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "M"
                    ],
                    "last": "Weiner",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Trinh",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Heller",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "S"
                    ],
                    "last": "Evans",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [
                        "H"
                    ],
                    "last": "Adams",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "J Am Coll Cardiol",
            "volume": "67",
            "issn": "21",
            "pages": "2519--2551",
            "other_ids": {}
        },
        "BIBREF18": {
            "ref_id": "b18",
            "title": "Guidelines on the diagnosis and management of heparin-induced thrombocytopenia: second edition",
            "authors": [
                {
                    "first": "H",
                    "middle": [],
                    "last": "Watson",
                    "suffix": ""
                },
                {
                    "first": "S",
                    "middle": [],
                    "last": "Davidson",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Keeling",
                    "suffix": ""
                }
            ],
            "year": 2012,
            "venue": "Br J Haematol",
            "volume": "159",
            "issn": "",
            "pages": "528--540",
            "other_ids": {}
        },
        "BIBREF19": {
            "ref_id": "b19",
            "title": "Heparin and anticoagulation",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Onishi",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "St Ange",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "S"
                    ],
                    "last": "Dordick",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [
                        "J"
                    ],
                    "last": "Linhardt",
                    "suffix": ""
                }
            ],
            "year": 2016,
            "venue": "Frontiers in Bioscience. Landmark",
            "volume": "21",
            "issn": "",
            "pages": "1372--92",
            "other_ids": {}
        },
        "BIBREF20": {
            "ref_id": "b20",
            "title": "Risk for heparin-induced thrombocytopenia with unfractionated and low-molecularweight heparin thromboprophylaxis: a meta-analysis",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Martel",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Lee",
                    "suffix": ""
                },
                {
                    "first": "P",
                    "middle": [
                        "S"
                    ],
                    "last": "Wells",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Blood",
            "volume": "106",
            "issn": "8",
            "pages": "2710--2715",
            "other_ids": {}
        },
        "BIBREF21": {
            "ref_id": "b21",
            "title": "The HIT Expert Probability (HEP) Score: a novel pre-test probability model for heparin-induced thrombocytopenia based on broad expert opinion",
            "authors": [
                {
                    "first": "A",
                    "middle": [],
                    "last": "Cuker",
                    "suffix": ""
                },
                {
                    "first": "G",
                    "middle": [],
                    "last": "Arepally",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "A"
                    ],
                    "last": "Crowther",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Rice",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Datko",
                    "suffix": ""
                },
                {
                    "first": "K",
                    "middle": [],
                    "last": "Hook",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "J Thromb Haemost",
            "volume": "8",
            "issn": "12",
            "pages": "2642--50",
            "other_ids": {}
        },
        "BIBREF22": {
            "ref_id": "b22",
            "title": "Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia",
            "authors": [
                {
                    "first": "L",
                    "middle": [],
                    "last": "Lin",
                    "suffix": ""
                },
                {
                    "first": "L",
                    "middle": [],
                    "last": "Lu",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [],
                    "last": "Cao",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "Emerg Microbes Infect",
            "volume": "9",
            "issn": "1",
            "pages": "727--759",
            "other_ids": {}
        },
        "BIBREF23": {
            "ref_id": "b23",
            "title": "Clinical observations of low molecular weight heparin in relieving inflammation in COVID-19 patients: A retrospective cohort study",
            "authors": [
                {
                    "first": "C",
                    "middle": [],
                    "last": "Shi",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Wang",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Yang",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Cai",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Zeng",
                    "suffix": ""
                },
                {
                    "first": "F",
                    "middle": [],
                    "last": "Cheng",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Liu",
                    "suffix": ""
                },
                {
                    "first": "T",
                    "middle": [],
                    "last": "Zhou",
                    "suffix": ""
                },
                {
                    "first": "B",
                    "middle": [],
                    "last": "Deng",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "Y",
                    "middle": [],
                    "last": "Zhang",
                    "suffix": ""
                }
            ],
            "year": null,
            "venue": "",
            "volume": "2020",
            "issn": "",
            "pages": "",
            "other_ids": {
                "DOI": [
                    "10.1101/2020.03.28.20046144"
                ]
            }
        },
        "BIBREF24": {
            "ref_id": "b24",
            "title": "Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy",
            "authors": [
                {
                    "first": "N",
                    "middle": [],
                    "last": "Tang",
                    "suffix": ""
                },
                {
                    "first": "H",
                    "middle": [],
                    "last": "Bai",
                    "suffix": ""
                },
                {
                    "first": "X",
                    "middle": [],
                    "last": "Chen",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [],
                    "last": "Gong",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Li",
                    "suffix": ""
                },
                {
                    "first": "Z",
                    "middle": [],
                    "last": "Sun",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Thromb Haemost",
            "volume": "18",
            "issn": "5",
            "pages": "1094--1103",
            "other_ids": {}
        },
        "BIBREF25": {
            "ref_id": "b25",
            "title": "In uremia, plasma levels of anti-protein C and anti-protein S antibodies are associated with thrombosis",
            "authors": [
                {
                    "first": "D",
                    "middle": [],
                    "last": "Molino",
                    "suffix": ""
                },
                {
                    "first": "De",
                    "middle": [],
                    "last": "Lucia",
                    "suffix": ""
                },
                {
                    "first": "D",
                    "middle": [],
                    "last": "Marotta",
                    "suffix": ""
                },
                {
                    "first": "R",
                    "middle": [],
                    "last": "Perna",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [],
                    "last": "Lombardi",
                    "suffix": ""
                },
                {
                    "first": "C",
                    "middle": [],
                    "last": "Cirillo",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [],
                    "last": "",
                    "suffix": ""
                }
            ],
            "year": 2005,
            "venue": "Kidney Int",
            "volume": "68",
            "issn": "3",
            "pages": "1223--1232",
            "other_ids": {}
        },
        "BIBREF26": {
            "ref_id": "b26",
            "title": "Measuring anti-factor xa activity to monitor low-molecular-weight heparin in obesity: a critical review",
            "authors": [
                {
                    "first": "G",
                    "middle": [],
                    "last": "Egan",
                    "suffix": ""
                },
                {
                    "first": "M",
                    "middle": [
                        "H"
                    ],
                    "last": "Ensom",
                    "suffix": ""
                }
            ],
            "year": 2015,
            "venue": "Can J Hosp Pharm",
            "volume": "68",
            "issn": "1",
            "pages": "33--47",
            "other_ids": {}
        },
        "BIBREF27": {
            "ref_id": "b27",
            "title": "The versatile heparin in COVID-19",
            "authors": [
                {
                    "first": "J",
                    "middle": [],
                    "last": "Thachil",
                    "suffix": ""
                }
            ],
            "year": 2020,
            "venue": "J Thromb Haemost",
            "volume": "18",
            "issn": "5",
            "pages": "1020--1022",
            "other_ids": {}
        },
        "BIBREF28": {
            "ref_id": "b28",
            "title": "Identification of an endothelial cell cofactor for thrombin-catalyzed activation of protein C",
            "authors": [
                {
                    "first": "C",
                    "middle": [
                        "T"
                    ],
                    "last": "Esmon",
                    "suffix": ""
                },
                {
                    "first": "W",
                    "middle": [
                        "G"
                    ],
                    "last": "Owen",
                    "suffix": ""
                }
            ],
            "year": 1981,
            "venue": "Proc Natl Acad Sci",
            "volume": "78",
            "issn": "4",
            "pages": "2249--52",
            "other_ids": {}
        },
        "BIBREF29": {
            "ref_id": "b29",
            "title": "Factor V is an anticoagulant cofactor for activated protein C during inactivation of factor Va",
            "authors": [
                {
                    "first": "T",
                    "middle": [
                        "J"
                    ],
                    "last": "Cramer",
                    "suffix": ""
                },
                {
                    "first": "J",
                    "middle": [
                        "H"
                    ],
                    "last": "Griffin",
                    "suffix": ""
                },
                {
                    "first": "A",
                    "middle": [
                        "J"
                    ],
                    "last": "Gale",
                    "suffix": ""
                },
                {
                    "first": "V",
                    "middle": [],
                    "last": "Factor",
                    "suffix": ""
                }
            ],
            "year": 2010,
            "venue": "Pathophysiol Haemost Thromb",
            "volume": "37",
            "issn": "1",
            "pages": "17--23",
            "other_ids": {}
        }
    },
    "ref_entries": {
        "FIGREF1": {
            "text": "Fig. 1. Mechanism of action of UFH and LMWH with the major ligand-binding interactions involved. One of the key proteins for the activity of heparin is antithrombin, a serine protease inhibitor (SERPINSC1) that inactivates several clotting factors. Mechanistically, heparin binds to antithrombin, thus exposing the antithrombin protease inhibitor binding site and forming equimolecular complexes with its ligands. Antithrombin uses unique and extensive conformational change mechanisms to inhibit its protease ligands [8]. Heparin increases by orders of magnitude the tendency of antithrombin to interact with a number of plasma proteins. The resulting complex, in particular with thrombin (factor IIa) and factors IXa, Xia, and Xa, inhibits the protease activities of these clotting factors. Heparin indeed works as an antithrombin-protease-inhibiting cofactor without being consumed, and, once the antithrombin-protease complex is formed, heparin is released in its intact conformation, thus repeatedly activating new antithrombin molecules. Heparin biological activity crucially depends indeed on the endogenous antithrombin anticoagulant activity. The role of antithrombin is pivotal in coagulation regulation by shifting thrombin from procoagulant to anticoagulant activity. The presence of heparin dramatically increases the complex stability of antithrombin with the above-mentioned coagulation factors [8, 9]. One important difference between UFH and LMWH is that the interaction of antithrombin with UHF almost equally induces inhibition and degradation of both Xa and thrombin, while LMWH preferentially determines degradation of factor Xa. Various other potential benefits of heparin in COVID-19 have been put forward recently [28].",
            "latex": null,
            "type": "figure"
        },
        "FIGREF2": {
            "text": "Scheme of the anticoagulant activity of the protein C anticoagulant pathway. Protein C is activated by thrombin (not shown), forming APC",
            "latex": null,
            "type": "figure"
        },
        "TABREF1": {
            "text": "Perna et al.: COVID-19 and HD www.karger.com/kbr \u00a9 2020 The Author(s). Published by S. Karger AG, Basel DOI: 10.1159/000508460",
            "latex": null,
            "type": "table"
        },
        "TABREF2": {
            "text": "Proposed laboratory test profile to monitor LMWH therapy and the risk of adverse reactions",
            "latex": null,
            "type": "table"
        }
    },
    "back_matter": []
}